Relmada Q2 FY26 net loss widens to $12.9 million; R&D expense rises to $8.4 million
RLMD•Cash position and program timeline
- Cash, cash equivalents, and short-term investments climbed to $217.7 million; operations are expected to be funded through 2029, including NDV-01 Phase 3.
- NDV-01 IND filing is targeted by year-end 2026, with Phase 3 RESCUE to start upon clearance; sepranolone IND is also expected by year-end 2026.
Q2 financial results and expense trends
- Relmada posted a Q2 net loss of $12.9 million, or $0.11 per share, versus a $9.9 million loss a year earlier.
- R&D expense more than doubled to $8.4 million, driven by higher NDV-01 and sepranolone study costs and manufacturing and storage.
- G&A expense fell 10.81% to $6.6 million on lower stock-based and employee compensation, partly offset by higher consulting and rights expense.
